Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack

Angion

Status and phase: Terminated; Phase 2

Conditions: Myocardial Infarction

Treatments: Drug: BB3; Drug: Normal saline

Study type: Interventional

Funder types: Industry; NIH

Identifiers

NCT01539590

001-10

5R44HL091699 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The study will evaluate the effect of BB3 to preserve myocardial (heart) tissue and function following myocardial infarction (heart attack).

Full description

Percutaneous coronary intervention (PCI) has become the mainstay for treatment of ST-segment elevation myocardial infarction (STEMI). Whereas early recanalization undoubtedly salvages myocardial tissue, reperfusion following prolonged ischemia can also exacerbate injury. Infarct size needs to be limited, and the conditions favoring adaptive ventricular healing and remodeling optimized because in patients with acute myocardial infarction (AMI) who do not die of out-of-hospital arrhythmias, long-term prognosis is dependent on the amount of myocardium that is lost, and the outcome of ventricular remodeling. Angion Biomedical Corp. has identified BB3, a small molecule mimetic of hepatocyte growth factor/scatter factor (HGF/SF) whose activity is expected to preserve tissue viability and attenuate dysfunction in the setting of organ injury while obviating the logistical difficulties associated with gene or protein therapy. HGF/SF is a naturally occurring cell survival factor that holds significant therapeutic potential. BB3 has been shown to possess HGF/SF activities, including protection against heart injury following myocardial infarction. This study is designed to evaluate clinical efficacy of BB3 in patients presenting with acute ST segment elevation myocardial infarction (A-STEMI) who undergo PCI.

Enrollment: 5 patients

Sex: All

Ages: 21 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. The subject or legally authorized representative has been informed of the nature of the study, agrees to its provisions, and has been provided and signed written informed consent, approved by the Institutional Review Board (IRB), prior to performance of any study related procedure including screening procedure.
2. Subject is male or female
3. Subject is 21 to 80 years of age
4. Estimated body weight < 120 kg and BMI < 40
5. Subject is experiencing clinical symptoms consistent with acute myocardial infarction (AMI) (e.g., chest pain, arm pain, etc.,) >30 minutes duration and unresponsive to nitroglycerin; with ST segment elevation of more than 1 mm in at least two contiguous leads of ECG or new or presumed new onset bundle branch block (BBB)
6. Fulfills clinical center's criteria for primary PCI
7. PCI will be done within 12 hours of onset of STEMI.
8. The subject and his/her physician are willing to comply with the requirements of the study and the specified follow-up evaluations.
9. If female, either surgically sterile or post-menopausal or using acceptable contraception and agree to use effective birth control regimen during the study period. Men must agree to use condoms during the study period. Women of child bearing potential must have a negative urine or serum pregnancy test.
10. In the opinion of the Investigator, the subject is capable of understanding and complying with the protocol.

Exclusion criteria

1. Pregnant or nursing subjects and those who plan pregnancy in the period up to 6 months following index procedure.

2. Cardiogenic shock (Killip class 4) or cardiac arrest

3. History of prior myocardial infarction or pre-existing Q waves on ECG

4. An elective surgical procedure is planned that would necessitate interruption of anti-platelet agents during the first six months post enrollment;

5. Any contraindication to undergo MRI imaging. This will include any of the following exclusions:

   1. Cardiac pacemaker or implantable defibrillator;
   2. Non-MRI-compatible aneurysm clip;
   3. Neural stimulator (e.g., TENS-Unit);
   4. Any implanted or magnetically activated device (e.g., insulin pump);
   5. Any type of non-MRI-compatible metallic ear implant;
   6. Metal shavings in the orbits;
   7. Any metallic foreign body, shrapnel, or bullet in a location which the physician feels would present a risk to the subject;
   8. Any history indicating contraindication to MRI, including claustrophobia or allergy to gadolinium;
   9. Inability to follow breathhold instructions or to maintain a breathhold for >15 seconds;
   10. Irregular cardiac rhythm not expected to resolve after treatment of the acute cardiac condition (e.g., chronic atrial fibrillation)
   11. Known hypersensitivity or contraindication to gadolinium contrast.

6. Subject has active bleeding or a history of bleeding diathesis or coagulopathy (including heparin induced thrombocytopenia), or refusal to receive blood transfusions if necessary;

7. Subjects presenting with cardiogenic shock (SBP <80 mmHg for >30 minutes, or requiring IV pressors or emergency IABP for hypotension treatment) or cardiopulmonary resuscitation prior to randomization;

8. History of intracerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic stroke; stroke or transient ischemic attack within the past 6 months, or any permanent residual neurologic defect; known preceding cardiac ventricular arrhythmia

9. Impaired renal function (eGFR of ≤30 ml/min/1.73m2, as estimated by the MDRD4v equation) or on dialysis.

10. Impaired hepatic function (ALT > 2x upper limit of normal, or a total bilirubin greater than 1.5 x upper limit of normal).

11. Currently participating in or has participated in an investigational drug or medical device study within 30 days or 5 half-lives, whichever is longer, prior to enrollment into this study

12. Have an active malignancy or history of solid, metastatic, or hematologic malignancy with the exception of basal or squamous cell carcinoma of the skin that has been removed

13. History of positive human immunodeficiency virus (HIV) test

14. History of rheumatoid arthritis

15. History of proliferative retinopathy or laser surgery for retinopathy

16. Subjects who require cytochrome P450 1A2 (CYP1A2) inhibitors, ciprofloxacin and/or fluvoxamine (Luvox®)

17. Subject has other medical illness or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the protocol, confound the data interpretation or is associated with a limited life expectancy of less than 6 months,

18. Any significant medical condition which in the Investigator's opinion may interfere with the subject's optimal participation in the study;

19. Subject has a known hypersensitivity or allergy to stainless steel, nickel, cobalt chromium, nitinol, titanium or known hypersensitivity or allergy to contrast media (e.g. rash) that cannot effectively be controlled by premedication with steroids and/or diphenhydramine. Subjects with hypersensitivity or allergy to any of the components of the device (structural, drug or polymer components) and subjects with true prior anaphylaxis to contrast media should not be enrolled

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

5 participants in 2 patient groups, including a placebo group

BB3

Experimental group

Description:

Daily intravenous administration of 2 mg/kg BB3 for four (4) days

Treatment:

Drug: BB3

Normal Saline

Placebo Comparator group

Description:

Daily intravenous administration for four (4) days

Treatment:

Drug: Normal saline